These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36959936)

  • 21. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
    de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
    Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
    Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
    PLoS Pathog; 2023 Jun; 19(6):e1011057. PubMed ID: 37352333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
    Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later.
    Milligan EC; Olstad K; Williams CA; Mallory M; Cano P; Cross KA; Munt JE; Garrido C; Lindesmith L; Watanabe J; Usachenko JL; Hopkins L; Immareddy R; Shaan Lakshmanappa Y; Elizaldi SR; Roh JW; Sammak RL; Pollard RE; Yee JL; Herbek S; Scobey T; Miehlke D; Fouda G; Ferrari G; Gao H; Shen X; Kozlowski PA; Montefiori D; Hudgens MG; Edwards DK; Carfi A; Corbett KS; Graham BS; Fox CB; Tomai M; Iyer SS; Baric R; Reader R; Dittmer DP; Van Rompay KKA; Permar SR; De Paris K
    Sci Transl Med; 2023 Mar; 15(685):eadd6383. PubMed ID: 36454813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS-CoV-2 infection.
    Zhang Y; Lu M; Thongpan I; Xu J; Kc M; Dravid P; Trivedi S; Sharma H; Liang X; Kapoor A; Peeples ME; Li J
    J Med Virol; 2023 Apr; 95(4):e28687. PubMed ID: 36941778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Site Specific N- and O-glycosylation mapping of the Spike Proteins of SARS-CoV-2 Variants of Concern.
    Shajahan A; Pepi L; Kumar B; Murray N; Azadi P
    Res Sq; 2022 Nov; ():. PubMed ID: 36415454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-Free Glycoengineering of the Recombinant SARS-CoV-2 Spike Glycoprotein.
    Ruhnau J; Grote V; Juarez-Osorio M; Bruder D; Mahour R; Rapp E; Rexer TFT; Reichl U
    Front Bioeng Biotechnol; 2021; 9():699025. PubMed ID: 34485255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
    Berry C; Pavot V; Anosova NG; Kishko M; Li L; Tibbitts T; Raillard A; Gautheron S; Cummings S; Bangari DS; Kar S; Atyeo C; Deng Y; Alter G; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Commun Med (Lond); 2023 May; 3(1):75. PubMed ID: 37237062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
    Villarraza J; Fuselli A; Gugliotta A; Garay E; Rodríguez MC; Fontana D; Antuña S; Gastaldi V; Battagliotti JM; Tardivo MB; Alvarez D; Castro E; Cassataro J; Ceaglio N; Prieto C
    Appl Microbiol Biotechnol; 2023 Jun; 107(11):3429-3441. PubMed ID: 37093307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of mutations on the plant-based production of recombinant SARS-CoV-2 RBDs.
    Ruocco V; Vavra U; König-Beihammer J; Bolaños Martínez OC; Kallolimath S; Maresch D; Grünwald-Gruber C; Strasser R
    Front Plant Sci; 2023; 14():1275228. PubMed ID: 37868317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Vaccine; ; . PubMed ID: 34750014
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.